AAVantgarde Bio
AAVantgarde Bio, based in Milan, is developing gene therapies for inherited retinal disorders. The founder, Professor Alberto Auricchio, is a highly recognized scientist and a pioneer in the field of gene therapy. The company’s technology builds on existing AAV, or adeno-associated virus-based platforms, which are the main viral vector technology used in gene therapy applications. The company is a spin-off of TIGEM, an international research institute based in Naples that is owned and managed by the Telethon Foundation.
Sector
Biopharmaceuticals
Strategy
Telethon
Status
Live
Website
www.aavantgardebio.com
Related News
AAVantgarde announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the treatment of Stargardt disease
AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease
AAVantgarde Receives FDA IND Clearance to Progress Stargardt Disease program AAVB-039
AAVantgarde presents positive clinical data from its AAVB-081 program for Usher 1B and preclinical data from its AAVB-039 program for Stargardt at the ARVO 2025 annual meeting
Rasmus Holm-Jorgensen appointed CFO at AAVantgarde
AAVantgarde Bio announces FDA Orphan Drug Designation for AAVB-081 for the treatment of Usher Syndrome type 1B Retinitis Pigmentosa
AAVantgarde Founder and CSO is elected as President of the European Society of Gene and Cell Therapy (ESGCT)
AAVantgarde appoints Ms. Lauren Kaskiel as Chief Business Officer
AAVantgarde announces first patient dosed with AAVB-081 in FIH Phase 1/2 LUCE-1 study for retinitis pigmentosa related to USH1B
AAVantgarde appoints Dr. Jayashree Sahni as Chief Medical Officer
AAVantgarde appoints Nina (Ekaterini) Kotsopoulou, PhD, as Chief Technical Officer
AAVantgarde appoints Dr. Peter K. Kaiser to the Board of Directors
AAVantgarde appoints Michael Heffernan as Chairman of its Board of Directors
AAVantgarde appoints Dr. Doug Kerr to the Board of Directors
AAVantgarde closes €61 million Series A financing to advance two therapeutic programs into the clinic
AAVantgarde Founder and Chief Scientific Officer, Professor Alberto Auricchio, is elected as Vice President of the European Society of Gene and Cell Therapy
AAVantgarde Bio appoints Dr. Natalia Misciattelli as Chief Executive Officer
AAVantgarde announces the appointment of Naveed Shams, M.D., Ph.D. as Chief Development and Medical Officer
AAVantgarde Bio appoints Ram Palanki as Chairman of its Board of Directors
Sofinnova Partners announces three new investments from its fund dedicated to Italian scientific research
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.